TScan Therapeutics (TCRX) Stock Forecast & Price Target

TScan Therapeutics is supported by encouraging Cohort C data, with all 13 patients achieving complete donor chimerism as of August 27 and a ~20% 6-month relapse rate in 14 patients that compares favorably with historical relapse rates of ~45% in MRD+ and ~20% in MRD- patients post HSCT. Management’s ~75% reduction in force is expected to deliver about $55M in cumulative savings through YE:27, and the company’s 2Q:26 cash balance of $100M is projected to fund operations into 4Q:27. Despite that improved runway, the company still needs additional capital to reach clinical milestones for its in vivo programs, while upcoming updates in 4Q:26 and 2Q:27 provide identifiable catalysts for further validation.

TScan Therapeutics is facing a structurally weaker investment case after pausing its heme program, because despite compelling Phase 1 ALLOHA signals, the company is redirecting capital to an earlier-stage solid-tumor strategy with PRAME and MAGE-A4 only entering IND-enabling studies and no guarantee of clinical success. The 75% workforce reduction, elimination of internal manufacturing, and $55M in cumulative savings extend cash runway only into 4Q27, which appears to cover just the first planned in vivo study and implies a likely need for additional financing, a partnership, or another strategic transaction. With the prior clinical and strategic rationale for TSC-100 and TSC-101 now deferred, the company faces a meaningful financing overhang and heightened execution risk across all programs in Phase I development.